Maria G. Vitale

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2026

Gene-expression signature predicts autoimmune toxicity in metastatic melanoma.

Gene-expression signature predicts autoimmune toxicity in metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: June 02, 2025

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 08, 2025

Advances in Melanoma and Skin Cancers.

Advances in Melanoma and Skin Cancers.

Journal: International journal of molecular sciences

Published: January 23, 2025

ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma.

ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma.

Journal: International journal of molecular sciences

Published: October 02, 2024

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

Journal: NEJM evidence

Published: September 24, 2024

Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.

Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: February 29, 2024

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 02, 2023

Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.

Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.

Journal: Melanoma research

Published: July 04, 2023

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Journal: Nature communications

Published: May 15, 2023

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

Journal: Journal of translational medicine

Published: December 12, 2022

Immunotherapy Assessment: A New Paradigm for Radiologists.

Immunotherapy Assessment: A New Paradigm for Radiologists.

Journal: Diagnostics (Basel, Switzerland)

Published: November 17, 2022

Showing 1-12 of 53

Last Updated: 09/26/2026